{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:20:25Z","timestamp":1778102425389,"version":"3.51.4"},"reference-count":26,"publisher":"European Respiratory Society (ERS)","issue":"5","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,10,5]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Benralizumab is an interleukin-5 receptor \u03b1-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy<jats:italic>versus<\/jats:italic>other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised.<\/jats:p><jats:p>We performed a matching-adjusted indirect comparison (MAIC) of benralizumab<jats:italic>versus<\/jats:italic>mepolizumab and reslizumab. Trials were selected through systematic review and evaluation of trial methods. Benralizumab patient-level data were weighted to match treatment-effect-modifying patient characteristics of comparator trials before indirect efficacy comparisons.<\/jats:p><jats:p>After matching adjustment, benralizumab and mepolizumab reduced exacerbations<jats:italic>versus<\/jats:italic>placebo by 52% and 49%, respectively (rate ratio [RR] 0.94, 95% CI 0.78\u20131.13; n=1524) and reduced the rate of exacerbations requiring hospitalisation\/emergency department visit by 52% and 52%, respectively (RR 1.00, 95% CI 0.57\u20131.75; n=1524). Benralizumab and mepolizumab similarly improved pre-bronchodilator forced expiratory volume in 1\u2005s at 32\u2005weeks (difference 0.03\u2005L, 95% CI \u22120.06\u20130.12; n=1443). Benralizumab and reslizumab patient populations were too dissimilar to generate a sufficient effective sample size to produce a reliable estimate for MAIC.<\/jats:p><jats:p>MAIC is a robust way to indirectly compare treatment efficacies from trials with heterogeneous patient populations. When baseline patient characteristics were matched across asthma trials, benralizumab and mepolizumab yielded similar efficacy.<\/jats:p>","DOI":"10.1183\/13993003.01393-2018","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T11:49:49Z","timestamp":1539258589000},"page":"1801393","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":80,"title":["Matching-adjusted indirect comparison of benralizumab<i>versus<\/i>interleukin-5 inhibitors for the treatment of severe asthma: a systematic review"],"prefix":"10.1183","volume":"52","author":[{"given":"Arnaud","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Husereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarowar","family":"Golam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd\u00a0Kashif","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"2024102100391968000_52.5.1801393.1","first-page":"848","article-title":"Economic burden of illness among patients with severe asthma in a managed care setting","volume":"22","author":"Chastek","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2024102100391968000_52.5.1801393.2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2500\/aap.2015.36.3908","article-title":"Severe asthma: epidemiology, burden of illness, and heterogeneity","volume":"36","author":"Lang","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"2024102100391968000_52.5.1801393.3","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210531"},{"key":"2024102100391968000_52.5.1801393.4","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-016-0029-3"},{"key":"2024102100391968000_52.5.1801393.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.039"},{"key":"2024102100391968000_52.5.1801393.6","unstructured":"Teva Pharmaceutical Industries Ltd. CINQAIR\u00ae (reslizumab) label. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf. Date last updated: March 2016. Date last accessed: March 23, 2018."},{"key":"2024102100391968000_52.5.1801393.7","unstructured":"GlaxoSmithKline LLC. NUCALA\u00ae (mepolizumab) label. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf. Date last updated: November 2015. Date last accessed: April 13, 2018."},{"key":"2024102100391968000_52.5.1801393.8","unstructured":"AstraZeneca. FASENRA\u2122 (benralizumab) label. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761070s000lbl.pdf. Date last accessed: April 13, 2018."},{"key":"2024102100391968000_52.5.1801393.9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"2024102100391968000_52.5.1801393.10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102100391968000_52.5.1801393.11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"2024102100391968000_52.5.1801393.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024102100391968000_52.5.1801393.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024102100391968000_52.5.1801393.14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.rmed.2016.12.009","article-title":"Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison","volume":"123","author":"Cockle","year":"2017","journal-title":"Respir Med"},{"key":"2024102100391968000_52.5.1801393.15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cea.12853","article-title":"Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials","volume":"47","author":"Cabon","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"2024102100391968000_52.5.1801393.16","first-page":"OA2903","article-title":"Reslizumab versus benralizumab in patients with inadequately controlled asthma: a Bayesian network meta-analysis","volume":"50","author":"Casale","year":"2017","journal-title":"Eur Respir J"},{"key":"2024102100391968000_52.5.1801393.17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"2024102100391968000_52.5.1801393.18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/JBM.S104074","article-title":"Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 versus two recombinant factor VIII for the prophylactic treatment of severe hemophilia A","volume":"7","author":"Pocoski","year":"2016","journal-title":"J Blood Med"},{"key":"2024102100391968000_52.5.1801393.19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"2024102100391968000_52.5.1801393.20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0103"},{"key":"2024102100391968000_52.5.1801393.21","unstructured":"Phillippo DM , Ades AE , Dias S , et\u00a0al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. December 2016. Sheffield, University of Sheffield, 2016."},{"key":"2024102100391968000_52.5.1801393.22","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2024102100391968000_52.5.1801393.23","unstructured":"NICE STA. 2012. Specification for manufacturer\/sponsor submission of evidence. https:\/\/www.nice.org.uk\/media\/default\/about\/what-we-do\/nice-guidance\/nice-technologyappraisals\/specification-for-manufacturer-sponsor-submission-of-evidence-june-2012.doc Date last accessed: June 2017."},{"key":"2024102100391968000_52.5.1801393.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"2024102100391968000_52.5.1801393.25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102100391968000_52.5.1801393.26","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01393-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:00:21Z","timestamp":1740380421000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01393-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,11,29]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1183\/13993003.01393-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01393-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}